RBC Capital Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $54
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi maintains an Outperform rating on Intellia Therapeutics (NASDAQ:NTLA) but lowers the price target from $60 to $54.
August 09, 2024 | 7:43 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital analyst Luca Issi maintains an Outperform rating on Intellia Therapeutics but lowers the price target from $60 to $54.
The Outperform rating suggests continued confidence in the company's performance, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100